Cargando…
Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers
The first gene therapy product, recombinant adenovirus human p53 (rAd-p53), has been approved by CFDA since 2013. During these years, most of the clinical trials and the relevant basic research were carried out by Chinese oncologists. Gendicine was proved to be a safe and promising gene therapy drug...
Autores principales: | Li, Yi, Guo, Wei, Li, Xiuqin, Zhang, Jianguo, Sun, Moyi, Tang, Zhangui, Ran, Wei, Yang, Kai, Huang, Guilin, Li, Longjiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595718/ https://www.ncbi.nlm.nih.gov/pubmed/34785635 http://dx.doi.org/10.1038/s41368-021-00145-1 |
Ejemplares similares
-
Comment: Head and Neck Oncology
Publicado: (2014) -
Consensus standards for the process of cancer care: a modified expert panel method applied to head and neck cancer. South and West Expert Tumour Panel for Head and Neck Cancer.
por: Birchall, M. A.
Publicado: (1998) -
Verbalization, Categorization, and Evaluation of Fundamental Surgical Skills: An Expert Consensus in Open Head and Neck Surgery
por: Mitani, Sohei, et al.
Publicado: (2021) -
A consensus-based transparency checklist
por: Aczel, Balazs, et al.
Publicado: (2019) -
The role of extracellular vesicles from different origin in the microenvironment of head and neck cancers
por: Xie, Changqing, et al.
Publicado: (2019)